12 Results for "

human GPR35

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "human GPR35" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-B1816
CAS No.: 37762-06-4
Synonyms: M&B 22948
Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35) agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107536
CAS No.: 1164500-72-4
Purity:  96.09%
Target:  

GPR35 CXCR

ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) . ML 145 has no significant activity for GPR35 at either rodent ortholog .
loading...
    loading...
Cat. No.: HY-W018158
CAS No.: 4790-08-3
Synonyms: 5,6-Dihydroxyindole-2-carboxylic acid
DHICA (5,6-Dihydroxyindole-2-carboxylic acid) is an eumelanin building block, GPR35 agonist and melanin synthesis intermediate. DHICA activates GPR35, triggering dynamic mass redistribution and β-arrestin translocation. DHICA interacts with DNA and interferes with Fpg activity . DHICA promotes the generation of single-strand breaks in plasmid DNA. DHICA increases the activity and expression levels of SOD and Catalase. DHICA is applicable to research related to skin cancer and colon cancer .
loading...
    loading...
Cat. No.: HY-106481
CAS No.: 54867-56-0
Purity:  95.16%
Research Areas:  

Inflammation/Immunology

Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide .
loading...
    loading...
Cat. No.: HY-107539
CAS No.: 871085-49-3
Purity:  ≥99.0%
Target:  

GPR35

Research Areas:  

Others

GPR35 agonist 4 (compound 10) is a potent GPR35 agonist with an pEC50 of 5.86. GPR35 agonist 4 shows high potency human and rat GPR35. Mutation of arginine 3.36 eliminates agonist function of GPR35 agonist 4 .
loading...
    loading...
Cat. No.: HY-RS05705
Research Areas:  

Others

GPR35 Human Pre-designed siRNA Set A contains three designed siRNAs for GPR35 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-169302
CAS No.: 2855918-34-0
Target:  

GPR35

Research Areas:  

Cancer

GPR35 activator-1 (example 5) is a potent GPR35 activator with a Ki of 0.08 nM for human GPR35 .
loading...
    loading...
Cat. No.: HY-169301
CAS No.: 2994189-01-2
Target:  

GPR35

Research Areas:  

Cancer

Gpr35 modulator 1 (compound 1-18) is a potent modulator of Gpr35, with the IC50 of ≤ 100 nM in HEK293 cells stably transfected with human GPR35 .
loading...
    loading...
Cat. No.: HY-W1058476
CAS No.: 1443367-20-1
Target:  

GPR35 GPR55 Arrestin

Research Areas:  

Inflammation/Immunology Cancer

GPR35 agonist 6 is a potent and selective agonist targeting GPR35, with an EC50 of 12.1 nM against human GPR35. GPR35 agonist 6 activates the human splice variant GPR35b with comparable efficacy, showing an EC50 of 22.1 nM. GPR35 agonist 6 also exhibits weak GPR55 antagonistic activity, with an IC50 of 21.7 μM, and its agonistic activity towards GPR35 is significantly stronger than its antagonistic activity towards GPR55. GPR35 agonist 6 initiates GPR35 downstream signaling by inducing β-arrestin recruitment. GPR35 agonist 6 is used to investigate GPR35-mediated diseases, such as gastrointestinal lesions and gastric cancer .
loading...
    loading...
Cat. No.: HY-167706
CAS No.: 53882-13-6
Target:  

GPR35

Research Areas:  

Inflammation/Immunology

Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC50 values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design .
loading...
    loading...
Cat. No.: HY-107536R
CAS No.: 1164500-72-4
ML 145 (Standard) is the analytical standard of ML 145 (HY-107536). This product is intended for research and analytical applications. ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) . ML 145 has no significant activity for GPR35 at either rodent ortholog .
loading...
    loading...
Cat. No.: HY-P702306
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: G-protein coupled receptor 35; Kynurenic acid receptor; KYNA receptor
Species:  
Source:  
loading...
    loading...
  • 1